Transaction DateRecipientSharesTypePriceValue
5th October 2020Sandford D Smith5,936Open or private sale$30.00$178,080.00
5th October 2020Sandford D Smith5,936Exercise of derivative$7.37$43,748.32
15th July 2020Sandford D Smith6,667Open or private sale$29.00$193,343.00
15th July 2020Sandford D Smith6,667Exercise of derivative$6.21$41,402.07
10th July 2020Sandford D Smith6,667Open or private sale$28.00$186,676.00
10th July 2020Sandford D Smith6,667Exercise of derivative$6.21$41,402.07
8th July 2020Sandford D Smith1,434Exercise of derivative$6.21$8,905.14
8th July 2020Sandford D Smith1,434Open or private sale$27.00$38,718.00
7th July 2020Sandford D Smith6,510Open or private sale$26.00$169,260.00
7th July 2020Sandford D Smith5,232Exercise of derivative$6.21$32,490.72
Neuralstem
Neuralstem logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Neuralstem, Inc. operates as a biopharmaceutical company. It engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. The company was founded by I. Richard Garr, Karl Y. Johe and Merrill Solomon in 1996.


Ticker: CUR
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1357459
Employees: 6
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals